Znak nowych czasow: ruch pacjentow z borelioza doprowadzil do powstania publicznych przesluchan w USA i w Kanadzie. Ich rezultatem jest czesto prawna ochrona lekarzy leczacych borelioze dlugimi kuracjami antybiotykami.
Ponizej tekst prezydenta LDA w ktorym zaleca zakonczyc dyskryminacje LLMDs i odsunac Ubezpieczalnie od podejmowania decyzji na temat jaki pacjent zasluguje na jakie leczenie boreliozy.
Podobne przesluchania maja miejsce w tej chwili w Manitobie w Kanadzie.
Ale w wielu miejscach panuje ciagle konserwa. Jeden z LLMD Dr.M z BC (Kanada) zostal oskarzony o spowodowanie smierci pacjenta, ktory zmarl po podaniu dozylnego Rocephinu. W dodatku na czele komitetu sledczego postawiono faceta szeroko znanego ze swojej niecheci do pacjentow z borelioza i odmawiajacego im leczenia.
W koncu przeciez wiadomo, ze leczenie antybiotykami jest niebezpieczne, ale ciekaw jestem ktory z pacjentow wybierze model nieleczenia

. Zreszta mnostwo ludzi umiera po podaniu zwyklej aspiryny, zeby zobaczyc sprawe we wlasciwym swietle.
A teraz juz tekst przemowienia:
TESTIMONY TO MASSACHUSETTS COMBINED HEALTH COMMITTEE
By Pat Smith, President, Lyme Disease Association, Inc. 10-12-05
Personal Background: President of the Lyme Disease Association (LDA), Vice President of Political Affairs, International Lyme and Associated Diseases Society, (ILADS), a professional medical society, and former chair of the [New Jersey.] Governor's Lyme Disease Advisory Council, and former president of the Wall Township Board of Education. I also sat on the hearing panel for this committee in Ayer this past summer.
LDA Background: LDA is an all-volunteer national organization whose goals are education, prevention, research and patient support. LDA has supported research projects coast to coast, many published in peer review including JAMA, Infection, Neurology, and Proceedings of the National Academy of Science. LDA has five chapters (including one on the Cape, W. Barnstable), and 7 affiliates, and along with its CT affiliate, TFL, LDA is partnering with Columbia University to open an endowed chronic Lyme disease research center, the first of its kind in the world. 75% of the funds needed to open the center have been raised to date with actress Mary McDonnell, LDA's national spokesperson, supporting the project. LDA has the LymeAid 4 Kids fund for children without insurance to be evaluated for Lyme disease and that is supported by internationally acclaimed author Amy Tan.
Lyme is the most prevalent vector-borne disease in the US today. Research has shown the Lyme bacteria has the ability to enter the central nervous system less than a day's time after a tick bite, yet Lyme is rarely given the weight it deserves to be given. Witness the Center.s for Disease Control & Prevention's (CDC) recent expenditures on Lyme disease: $7M annually.
Lack of funding and focus have lead to lack of physician education. It has also created a climate of fear for potential treating physicians who are often afraid to diagnose and treat patients due to medical board investigations nationwide of those treating chronic Lyme disease, investigations often initiated by insurers or other physicians who do not recognize chronic disease. Sanctions including supervision, fines, losing ability to treat Lyme patients, and license suspension and revocation have been imposed. This in turn has created a situation where patients are unable to obtain diagnosis, treatment, insurance reimbursement, disability, education or even understanding from their families and peers.
The need for more treating physicians becomes apparent when one examines the CDC reported case numbers which range from 20,000-24,000 annually nationwide, numbers which represent only 10% of actual cases meeting the CDC surveillance criteria according to the CDC, (Footnote 1) thus up to 240,000 new cases actually occur annually that do meet the CDC criteria.
That represents almost ¼ M new cases, a number that does not even include cases that fall outside the CDC surveillance criteria, incredibly, a number no one knows, because the CDC does not require record keeping on those cases. In fact, these physician-diagnosed cases are rejected by health departments if they are reported, because CDC does not accept them.
In 2004, New York (5100), Pennsylvania (3985), New Jersey (2698), and Massachusetts (1532) ranked 1,2,3,4 respectively in reported Lyme cases with Rhode Island 10th (249), New Hampshire 11th (226), Maine 12th (225), and Vermont 17th (50). Massachusetts continues to be 4th in 2005 reported cases (758).
Reported cases meet the surveillance criteria if the patient has a physician-diagnosed EM (bullseye) rash, or positive blood work and other system involvement. Studies have shown that the EM rash appears less than 50% of the time, and Lyme disease testing, especially the initial required screening test, the ELISA, is highly inaccurate. According to a letter from the NY DOH in 1996 to the CDC, if NY had followed the 2-tier testing requirement for 1995 cases, using first a + ELISA test requirement, 81% of non-EM cases would not have been confirmed. The CDC states that doctors should not use surveillance criteria for diagnosing Lyme, yet many physicians continue to do so.